Jonsson Sarah, Jonsson Håkan, Lundin Eva, Häggström Christel, Idahl Annika
Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.
Int J Cancer. 2025 Feb 1;156(3):529-537. doi: 10.1002/ijc.35180. Epub 2024 Sep 25.
The resemblance between fallopian tube cells and serous borderline ovarian tumors (BOTs) suggests a potential origin link, with salpingitis proposed as a contributing factor in the pathogenesis of BOT. This study aimed to explore the potential association between pelvic inflammatory disease (PID) and the risk of developing BOT. A national population-based case-control study in Sweden included women with BOT between 1999 and 2020 and 10 matched controls. Data from nationwide registers were analyzed using conditional logistic regression, adjusting for age, residential district, educational level and parity. Among 4782 cases and 45,167 controls, 2.0% of cases and 1.3% of controls had a history of PID. Previous PID was associated with an increased risk of BOT overall (aOR, 1.48; 95% CI, 1.19-1.85). Significant association was observed with serous tumors (aOR, 1.76; 95% CI, 1.36-2.29), while not with mucinous tumors (aOR, 0.95; 95% CI, 0.60-1.49). A dose-response relationship between number of PID episodes and serous BOT risk was noted (P < .001). This study demonstrates that PID is associated with increased risk of serous BOT, with a dose response relationship. The study highlights the potential serious implications of upper reproductive tract infections and inflammation. This underscores the need for further investigation of biological mechanisms and possible impact of PID on serous BOT development.
输卵管细胞与浆液性交界性卵巢肿瘤(BOT)之间的相似性表明它们可能存在起源上的联系,输卵管炎被认为是BOT发病机制中的一个促成因素。本研究旨在探讨盆腔炎性疾病(PID)与发生BOT风险之间的潜在关联。瑞典一项基于全国人口的病例对照研究纳入了1999年至2020年间患有BOT的女性以及10名匹配的对照。使用条件逻辑回归分析来自全国登记处的数据,并对年龄、居住地区、教育水平和生育情况进行了调整。在4782例病例和45167名对照中,2.0%的病例和1.3%的对照有PID病史。既往PID与总体BOT风险增加相关(比值比[aOR],1.48;95%置信区间[CI],1.19 - 1.85)。观察到与浆液性肿瘤有显著关联(aOR,1.76;95% CI,1.36 - 2.29),而与黏液性肿瘤无关(aOR,0.95;95% CI,0.60 - 1.49)。注意到PID发作次数与浆液性BOT风险之间存在剂量反应关系(P < 0.001)。本研究表明,PID与浆液性BOT风险增加相关,且存在剂量反应关系。该研究强调了上生殖道感染和炎症可能产生的严重影响。这凸显了进一步研究PID对浆液性BOT发生发展的生物学机制及可能影响的必要性。